Most Clicked AABB SmartBrief Stories

1. Stem cell researchers report reversal of multiple sclerosis symptoms

AABB SmartBrief | Mar 02, 2015

A U.K. study in the Journal of the American Medical Association found patients with multiple sclerosis regained mobility following stem cell therapy. The patients' stem cells were collected and reinfused after chemotherapy to effectively reset their immune systems, according to the researchers. The study did not include a control group. Telegraph (London) (tiered subscription model), The (03/01)

2. Study projects increasing rates of chronic kidney disease

AABB SmartBrief | Mar 04, 2015

Fifty-four percent of people ages 30 to 49 are likely to develop chronic kidney disease at some point during their lives. More than 13% of adults ages 30 and older have CKD, and that figure is expected to reach 14.4% by 2020 and jump to 16.7% a decade later, according to a study in the American Journal of Kidney Diseases. Researchers said they were surprised by the findings and expressed hope the study would draw more attention to the condition and spark research. Medical News Today (03/02)

3. Upcoming audioconference discusses clinical practice guidelines for platelet transfusions

AABB SmartBrief | Feb 27, 2015

On Tuesday, March 3, AABB's audioconference, "Guidelines for Platelet Use," will discuss the November 2014 publication of clinical practice guidelines for platelet transfusions. Based on a systematic review of available data and developed pursuant to the widely recognized GRADE methodology, these evidence-based guidelines are designed to provide clinicians with valuable guidance regarding when and at what dose to transfuse platelets in a variety of patient populations. These populations include individuals with hypoproliferative thrombocytopenia and patients undergoing procedures such as elective central venous catheter placement, lumbar puncture and major, elective, non-neuraxial surgery and coronary artery bypass graft surgery. Blank (02/27)

4. Stem cell study examines prevalence of leukemia-related mutations by age

AABB SmartBrief | Feb 27, 2015

Researchers in the U.K. have found that about 20% of people ages 50 to 60 and more than 70% of people older than 90 had leukemia-related mutations in blood stem cells, according to a study in the journal Cell Reports. The findings were based on an analysis of cell samples from 4,200 healthy people. HealthDay News (02/26) Independent (London) (tiered subscription model), The (02/26)

5. Experimental bone replacement technique is based on autologous stem cells

AABB SmartBrief | Mar 03, 2015

EpiBone is working to develop bone replacement techniques that use autologous stem cells grown on a matrix of decellularized animal-derived bone. The company has studied the method in pigs. Bloomberg (03/02)

6. Strains of HIV-1 originated from gorillas, study finds

AABB SmartBrief | Mar 03, 2015

A study in the Proceedings of the National Academy of Sciences found that the source of HIV-1 groups O and P originated with gorillas in Cameroon. Researchers said the transmission was most likely due to infected blood or tissue exposure during hunting for and butchering of bushmeat. The HIV-1 group O, the second most common HIV-1 strain, has infected about 100,000 people across Cameroon, Gabon, Nigeria and neighboring countries, while only two cases have been documented of HIV-1 group P infection. Reuters (03/02)

7. Portola's factor Xa inhibitor antidote receives FDA orphan designation

AABB SmartBrief | Feb 27, 2015

Portola Pharmaceuticals' experimental drug andexanet alfa received orphan drug status from the FDA for use in reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing serious uncontrolled bleeding or needing emergency surgical procedures. The drug is being evaluated in two late-stage trials. Healio (free registration) (02/26)

8. AABB submits comments on HCT/P draft guidances

AABB SmartBrief | Mar 02, 2015

AABB submitted comments to FDA on Monday, February 23, on two draft guidance documents related to human cells, tissues and cellular and tissue-based products, or HCT/Ps. Regarding the first guidance, "Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products," AABB's comments request clarification for a number of topics, including how to define the term "main function" as used in the phrase "The main function of the HCT/P," and the regulatory treatment of certain processes and tissue-based products. In addition, AABB recommends that FDA remove bone marrow aspirate as an example of tissues considered cells or nonstructural tissues. AABB expressed appreciation to FDA for publishing a second draft guidance, "Human Cells, Tissues, and Cellular and Tissue-Based Products from Adipose Tissue: Regulatory Considerations," which clarifies regulatory considerations for the manufacture and use of HCT/Ps from adipose tissue. Blank (03/02)

9. Reminder: PBM learning modules now available

AABB SmartBrief | Feb 26, 2015

Four PBM learning modules are now available. These modules include Patient Blood Management Module: Introduction; Optimizing Transfusion Benefits: Recognizing When Transfusions Are Helpful; Intraoperative Blood Conservation, Transfusion Strategies and Surgical Techniques; and Patient Blood Management for Coagulopathy. The modules provide educational content about PBM, an evidence-based, multidisciplinary approach to optimizing the care of patients who might need a blood transfusion. The modules can help providers determine the best strategies for managing blood-related issues for different patient populations. Interested individuals can purchase the PBM modules -- which are available individually and in institutional packages with multiple licenses -- online. A video about the modules is available, as well. Blank (11/17)

10. Treated mesenchymal stem cells migrate to inflamed tissue in preclinical test

AABB SmartBrief | Feb 27, 2015

A study in the journal Cell Reports found that mesenchymal stem cells treated with the compound Ro-31-8425 were more likely to reach inflamed tissue in mouse models. Researchers screened 9,000 small molecules to find those that promoted the expression of surface receptor CD11a, which interacts with a biomarker of inflammation. Scientist online, The (02/26)

Sign up for AABB SmartBrief

Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more